跳至主要内容
临床试验/NCT05495685
NCT05495685Unknown不适用

Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study

Changhai Hospital1 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2022年3月24日最近更新:
适应症

试验速览

阶段
不适用
入组人数
450
试验地点
1
主要终点
The sensitivity and specificity of multi-cancer early detection by the combined model in cancer arm and benign disease arm

研究概览

简要总结

DAYBREAK is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfDNA methylation, serum protein markers, blood miRNA markers and others, in which of 450 participants will be enrolled. The development and validation of the model will be conducted in participants with early stage cancers and benign disease through a two-stage approach. The sensitivity and specificity of the model in pancreatic cancer early detection will be evaluated.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

The sensitivity and specificity of multi-cancer early detection by the combined model in cancer arm and benign disease arm

时间窗: 12 months

次要结局

  • The difference of sensitivity and specificity in pancreatic cancer participants at different clinical stages.(12 months)
  • Sensitivity and specificity for detecting pancreatic cancer of a cfDNA methylation-based model, in combination with other biomarkers.(12 months)
  • Sensitivity and specificity for detecting pancreatic cancer of a the protein panel-based model, in combination with other biomarkers.(12 months)
  • Sensitivity and specificity of the blood miRNA-based model in detecting pancreatic cancer.(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Guo ShiWei

Associated Professor at the Institute of Pancreatic Surgery

Changhai Hospital

研究点 (1)

Loading locations...

相似试验